A jury says Boston Scientific Corp. must pay $431 million in damages in a patent dispute over the medical device maker’s drug-coated stents.
The company said that federal jury in Marshall, Texas reached the damages award in a patent infringement lawsuit brought by Dr. Bruce Saffran. The jury found that Boston Scientific’s Taxus Express and Taxus Liberte stents infringe on a patent that Saffran holds.
Boston Scientific argues the verdict is unsupported by evidence and the law. The Natick, Massachusetts-based company plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal.
Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque.
Was this article valuable?
Here are more articles you may enjoy.
What The Return of California’s ‘Death Discount’ Means for Litigation
Boeing 2011 Warning May Offer Clues into 2025 UPS Jet Crash
Musk’s X Probed by UK Over Grok’s Thousands of Sexualized Images
Cyber Breach Affected 750,000 Canadian Investors, Regulator Says